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Introduction {#path5054-sec-0001}
============

Accumulating evidence shows that aberrant glycosylation occurs frequently in cancer [1](#path5054-bib-0001){ref-type="ref"}, [2](#path5054-bib-0002){ref-type="ref"}. Alterations in glycosylation patterns regulate cancer development and progression, serve as important biomarkers, and provide a set of specific targets for diagnosis and therapeutic intervention [3](#path5054-bib-0003){ref-type="ref"}, [4](#path5054-bib-0004){ref-type="ref"}, [5](#path5054-bib-0005){ref-type="ref"}, [6](#path5054-bib-0006){ref-type="ref"}. The modifications most often associated with cancer include sialylation, β1,6‐GlcNAc‐branched *N‐*glycans, and core fucosylation [7](#path5054-bib-0007){ref-type="ref"}. Increased GlcNAc‐branched *N*‐glycan levels result from increased activity of *N‐*acetylglucosaminyltransferase V (GnT‐V) encoded by the mannoside acetylglucosaminyltransferase 5 (*MGAT5*) gene and are closely associated with cancer metastasis [8](#path5054-bib-0008){ref-type="ref"}. For example, an increase in GnT‐V‐dependent *N‐*glycan modifications enhances the invasiveness of glioma, colon cancer, and gastric cancer cells by regulating cell adhesion [1](#path5054-bib-0001){ref-type="ref"}, [9](#path5054-bib-0009){ref-type="ref"}, whereas core fucosylation, catalyzed by fucosyltransferase VIII, is involved in the expression of cancer biomarkers [10](#path5054-bib-0010){ref-type="ref"}.

CD147, also known as basigin or EMMPRIN, is a tumor‐associated transmembrane glycoprotein that belongs to the immunoglobulin superfamily [11](#path5054-bib-0011){ref-type="ref"}, [12](#path5054-bib-0012){ref-type="ref"}, [13](#path5054-bib-0013){ref-type="ref"}. As an extracellular inducer of MMPs, basigin is aberrantly expressed on the cell surface of various tumors and correlates with aggressive disease and poor prognosis [12](#path5054-bib-0012){ref-type="ref"}, [14](#path5054-bib-0014){ref-type="ref"}, [15](#path5054-bib-0015){ref-type="ref"}. In hepatocellular carcinoma (HCC), CD147/basigin is closely associated with carcinogenesis, EMT, and chemoresistance [16](#path5054-bib-0016){ref-type="ref"}, [17](#path5054-bib-0017){ref-type="ref"}, [18](#path5054-bib-0018){ref-type="ref"}, [19](#path5054-bib-0019){ref-type="ref"}. Mature CD147/basigin is highly glycosylated; *N‐*glycosylation accounts for almost half of the molecular weight [20](#path5054-bib-0020){ref-type="ref"}, [21](#path5054-bib-0021){ref-type="ref"}. CD147/basigin contains three *N‐*linked glycosylation sites (Asn44, Asn152, and Asn186), which contribute to both the high‐glycosylated form (∼40--60 kDa) and the low‐glycosylated form (∼32 kDa) [22](#path5054-bib-0022){ref-type="ref"}, [23](#path5054-bib-0023){ref-type="ref"}. Despite previous work, the contribution of glycans to CD147/basigin function remains unknown [24](#path5054-bib-0024){ref-type="ref"}, [25](#path5054-bib-0025){ref-type="ref"}.

Here, we report the clinical relevance of CD147/basigin‐β1,6‐branching in HCC and show that β1,6‐GlcNAc glycans are required for CD147/basigin to induce EMT and maintain the aggressiveness and malignant properties of HCC. In addition, we found that the PI3K/Akt pathway regulates GnT‐V‐mediated *N‐*glycosylation in HCC cells. With these data, we propose a model to explain how GnT‐V‐mediated glycosylation of CD147/basigin promotes HCC metastasis.

Materials and methods {#path5054-sec-0002}
=====================

Patients {#path5054-sec-0003}
--------

Sixty‐five HCC patients were recruited from the Eastern Hepatobiliary Hospital affiliated with The Second Military Medical University (Shanghai, China), and these patients provided written informed consent. Ethical approval for experiments involving human samples was granted by the Ethics Committee of The Fourth Military Medical University, and all experimental protocols were conducted in accordance with the relevant guidelines and regulations.

Cell culture and plasmids {#path5054-sec-0004}
-------------------------

Human HCC (HepG2), human normal hepatic (QZG), and human embryonic kidney (HEK293T) cells were obtained from the Institute of Cell Biology of the Chinese Academy of Sciences (Shanghai, China). The human HCC cell line (Huh‐7) was obtained from the Japanese Collection of Research Bioresources (JCRB, Osaka, Japan). QZG and HEK293T cells were cultured in RPMI 1640 medium (Gibco, New York, NY, USA); HepG2 and Huh‐7 cells were cultured in DMEM. All media were supplemented with 10% fetal bovine serum, 2 m[m]{.smallcaps} glutamine, 100 μg/ml penicillin, and 100 μg/ml streptomycin, and cells were incubated at 5% CO~2~ and 37 °C. All cells were authenticated by short tandem repeat profiling. The plasmids WT‐eGFP‐N1‐CD147 and N44Q/N152Q/N186Q (3Q)‐eGFP‐N1‐CD147 were used as described previously [22](#path5054-bib-0022){ref-type="ref"}.

Antibodies, immunohistochemical staining, and reagents {#path5054-sec-0005}
------------------------------------------------------

Antibody details are listed in the supplementary material, Table [S1](#path5054-supitem-0001){ref-type="supplementary-material"}. Rabbit anti‐CD147 and α‐tubulin were developed in our laboratory [26](#path5054-bib-0026){ref-type="ref"}. Formalin‐fixed, paraffin‐embedded tissues from HCC patients were stained with HAb18G antibody against CD147 (30 μg/ml) and PHA‐L (1:200) for β1,6‐branched *N‐*glycans as previously described [15](#path5054-bib-0015){ref-type="ref"}. The PI3K inhibitor LY294002 was purchased from Cell Signaling Technology (Danvers, MA, USA). TGF‐β1 (100‐210) was purchased from PeproTech (Rocky Hill, NJ, USA) and swainsonine (s9263) from Sigma‐Aldrich (St Louis, MO, USA).

In situ proximity ligation assay (PLA) {#path5054-sec-0006}
--------------------------------------

Duolink® In Situ Detection Reagents Red (Sigma‐Aldrich) were used according to the manufacturer\'s instructions. Rabbit anti‐CD147 (10 μg/ml) and biotinylated PHA‐L (1:200) were applied overnight at 4 °C, followed by mouse anti‐biotin. The PLA probes used were anti‐mouse immunoglobulin PLUS and anti‐rabbit‐MINUS. Images were acquired using a fluorescence microscope, and PLA signals were analyzed with the Duolink ImageTool (Sigma‐Aldrich).

siRNA transfection {#path5054-sec-0007}
------------------

Silencing was accomplished by transient transfection of siRNA oligonucleotides using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) following the manufacturer\'s instructions. We employed a pool of four RNAi oligonucleotides for *MGAT5* (ON‐TARGET plus, Dharmacon Smart Pool library, Lafayette, CO, USA), and an oligonucleotide from GenePharma (Shanghai, China) was used as the negative control (supplementary material, Table [S2](#path5054-supitem-0001){ref-type="supplementary-material"}).

Immunofluorescence {#path5054-sec-0008}
------------------

Immunofluorescence was performed as previously described [19](#path5054-bib-0019){ref-type="ref"}, but without detergent treatment. Briefly, actively growing Huh‐7 and HepG2 cells (5 × 10^4^) were seeded into dishes pre‐coated with 1% Matrigel (BD Biosciences, San José, CA, USA) and cultured overnight before being fixed with 4% paraformaldehyde and then blocked with 3% BSA in PBS for 0.5 h. Cells were incubated overnight with a mixture of biotinylated PHA‐L (1:200), mouse anti‐biotin, and rabbit anti‐CD147 (10 μg/ml); washed in PBS; and incubated with secondary fluorescent antibodies in PBS for 3 h. Nuclei were counterstained with DAPI (1:50 dilution; Vector Laboratories, Burlingame, CA, USA) and samples were visualized with a confocal microscope using Nikon NIS‐Elements software (Nikon, Tokyo, Japan).

In vitro invasion assays {#path5054-sec-0009}
------------------------

Huh‐7 cells (5 × 10^4^) were seeded onto Matrigel (BD Biosciences) in chambers (Merck Millipore, Darmstadt, Germany) inserted into 24‐well plates. Cell invasion was evaluated after 48 h using an inverted phase‐contrast microscope. Experiments were conducted in triplicate.

Quantitative real‐time PCR {#path5054-sec-0010}
--------------------------

Total RNA was extracted from cells using an Omega R6934‐01 Total RNA Kit (Omega Bio‐tek, Norcross, GA, USA) according to the manufacturer\'s protocol. cDNA synthesis was performed using PrimeScript RT Reagent (DRR037A; Takara Bio, Shiga, Japan) following the manufacturer\'s instructions. qPCR was performed on a Q3 LightCycler 2.0 instrument using SYBR Premix Ex Taq (DRR081A; Takara Bio), and results were calculated using the 2^−ΔΔCt^ method [27](#path5054-bib-0027){ref-type="ref"}. The *MMP‐1*, *MMP‐2*, *MMP‐9*, and *GAPDH* primers were synthesized by Shanghai Sangon Co (Shanghai, China) as described previously [28](#path5054-bib-0028){ref-type="ref"}, and the *LGALS3* and *MGAT5* primers were synthesized by Beijing Genomics Institute (BGI, Shenzhen, China).

Immunoprecipitation, western blotting, and lectin blotting {#path5054-sec-0011}
----------------------------------------------------------

Cells were harvested in lysis buffer and total protein concentrations were determined using a BCA Protein Assay Kit (Thermo Fisher Scientific, Waltham, MA, USA). Immunoprecipitation (IP) was performed using a Thermo Scientific Pierce co‐IP and cross‐linking kit according to the manufacturer\'s protocol. Briefly, after immobilizing the antibody for 3 h, the resin and lysate were incubated at 4 °C overnight. Afterwards, the proteins were eluted and analyzed by western blotting. An IgG antibody was immobilized as a negative control to assess nonspecific binding.

Proteins were separated by 10% SDS‐PAGE and transferred to PVDF membranes (Millipore, Billerica, MA, USA). After the membranes were blocked with 5% fat‐free milk, they were incubated with the indicated primary antibody at 4 °C overnight. The levels of β1,6‐GlcNAc‐branched *N*‐glycans were detected by lectin blotting. After blocking with 3% BSA in TBS (Tris‐buffered saline; 20 m[m]{.smallcaps} Tris and 0.5 [m]{.smallcaps} NaCl, pH 7.5), blots were incubated overnight with biotinylated PHA‐L (1:1000 dilution) [22](#path5054-bib-0022){ref-type="ref"}. After washing with PBST, the membranes were incubated with avidin--HRP (1:1000 dilution) for 1 h and then washed with PBST. Staining was detected with ECL western blotting detection reagents.

Fluorescence‐activated cell sorting (FACS) {#path5054-sec-0012}
------------------------------------------

Briefly, cells were harvested, washed twice with PBS, stained with fluorescein‐labeled PHA‐L (1:500) for 0.5 h on ice in the dark, and then washed twice [29](#path5054-bib-0029){ref-type="ref"}. The cells were analyzed by flow cytometry using FlowJo 7.6 software.

Statistical analysis {#path5054-sec-0013}
--------------------

Statistical analyses were performed using SPSS or GraphPad Prism 5. All data were analyzed by two‐tailed *t*‐tests or analysis of variance (ANOVA) as appropriate, and *p* \< 0.05 was considered statistically significant.

Results {#path5054-sec-0014}
=======

Upregulation of β1,6‐GlcNAc glycans on CD147/basigin in hepatocytes during TGF‐β1‐induced EMT {#path5054-sec-0015}
---------------------------------------------------------------------------------------------

EMT facilitates tumor metastasis and has recently been identified as a crucial driver of tumor progression [30](#path5054-bib-0030){ref-type="ref"}, [31](#path5054-bib-0031){ref-type="ref"}. In our research, a correlation between GnT‐V expression and EMT was observed in the cell lines tested. GnT‐V‐mediated glycosylation was elevated in QZG cells when EMT was induced by 24‐h treatment with 2.5 ng/ml TGF‐β1 (Figure [1](#path5054-fig-0001){ref-type="fig"}A--D). As shown in Figure [1](#path5054-fig-0001){ref-type="fig"}E, F, CD147/basigin was upregulated in QZG cells during TGF‐β1‐induced EMT. To further determine whether CD147/basigin glycosylation is associated with EMT, we analyzed the ratio of glycosylated/non‐glycosylated protein by western blotting. The increase in this ratio suggested the upregulation of CD147/basigin *N‐*glycosylation (Figure [1](#path5054-fig-0001){ref-type="fig"}G). Next, we detected the levels of β1,6‐GlcNAc glycans using PLA and IP with lectin blotting after TGF‐β1‐induced EMT. We observed an increase in CD147/basigin‐β1,6‐branching after TGF‐β1 treatment (Figure [1](#path5054-fig-0001){ref-type="fig"}H--J).

![The level of CD147‐β1,6‐GlcNAc‐branched structures is enhanced during EMT. (A) Cells were treated with 2.5 ng/ml TGF‐β1 for 24 h and cell lysates were analyzed by western blotting. (B) Real‐time PCR detection of MGAT5 mRNA levels in QZG cells stimulated with 2.5 ng/ml TGF‐β1 for 24 h. GAPDH was used as the normalization control. (C, D) Membrane levels of β1,6‐GlcNAc branching were measured by FACS with fluorescein‐labeled PHA‐L in QZG cells stimulated with TGF‐β1 for 24 h. (E--G) Western blotting of CD147, CD147/tubulin, and glycosylated/non‐glycosylated CD147 in control and TGF‐β1‐treated cells. (H, I) In situ PLA in control cells and cells treated with TGF‐β1. (H) Representative image. (I) Quantification. (J) QZG cells treated with TGF‐β1 were subjected to CD147/HAb18G immunoprecipitation (IP), western blotting, and lectin analyses. The results are shown as the mean ± SD (n = 3). Significance was determined by Student\'s t‐test (\*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001).](PATH-245-41-g001){#path5054-fig-0001}

CD147/basigin‐β1,6‐branching in HCC correlates with tumor metastasis {#path5054-sec-0016}
--------------------------------------------------------------------

We evaluated the clinical relevance of CD147/basigin‐β1,6‐branching levels in HCC patients. CD147/basigin is detected in both tumor and adjacent tissue (Figure [2](#path5054-fig-0002){ref-type="fig"}A). While our previous research found that CD147/basigin from human lung cancer tissue contains a high percentage of core fucose and β1,6‐GlcNAc glycans, the constitution of CD147/basigin glycosylation in HCC remained unclear [22](#path5054-bib-0022){ref-type="ref"}. Lectin histochemistry (Figure [2](#path5054-fig-0002){ref-type="fig"}A) of 14 HCC patient samples showed marked positive reactivity of biotinylated PHA‐L, demonstrating a high level of β1,6‐GlcNAc‐branched *N‐*glycans, whereas either negative or weak LCA signals were observed, confirming that core fucosylation is not universal in HCC tissue, as previously reported [9](#path5054-bib-0009){ref-type="ref"}. Because adjacent HCC tissues were positive for both PHA‐L and LCA, we next investigated β1,6‐glycans as a target. As the levels of CD147/basigin glycosylation in HCC were unknown, we assessed the levels of β1,6‐branched glycans in HCC tissue and cancer cell lines (Figure [2](#path5054-fig-0002){ref-type="fig"}B and supplementary material, Figure [S1](#path5054-supitem-0002){ref-type="supplementary-material"}) and found high levels on the plasma membrane. Furthermore, our PLA results (Figure [2](#path5054-fig-0002){ref-type="fig"}B) confirmed that CD147/basigin was highly glycosylated with β1,6‐branching in HCC, which is consistent with previous findings [32](#path5054-bib-0032){ref-type="ref"}, [33](#path5054-bib-0033){ref-type="ref"}. To determine the correlation with prognostic features in HCC, 51 patients with HCC were analyzed; only Barcelona clinic liver cancer (BCLC) stage was related to the level of CD147/basigin‐β1,6‐branched glycans (Table [1](#path5054-tbl-0001){ref-type="table-wrap"}, *p* = 0.016). Next, we further analyzed the correlation between BCLC stage and CD147/basigin‐β1,6‐branched glycans. Tissues from patients with stage C disease were markedly positive for CD147/basigin‐β1,6‐branched *N‐*glycans (PLA signal), whereas only weak signals were observed in tissues from patients with stage 0--A disease (*p* = 0.002, Figure [2](#path5054-fig-0002){ref-type="fig"}C, D); this modification increased as the staging progressed (Figure [2](#path5054-fig-0002){ref-type="fig"}D). These results indicate that the level of CD147/basigin‐β1,6‐branched glycans is linked to HCC metastasis and progression.

![Evaluation of CD147 and β1,6‐GlcNAc‐branched structures in human HCC tissues in different BCLC stages (n = 51). (A) Immunohistochemistry of HAb18G/CD147, β1,6‐GlcNAc‐branched N‐glycans, and core fucose in HCC tumor tissues and adjacent tissues (400×, n = 14). In total, 14/14 tumor tissues had positive signals for PHA‐L and β1,6‐GlcNAc‐branched structures, while 1/14 expressed core fucose. All adjacent tissues expressed both β1,6‐GlcNAc‐branched N‐glycans and core fucose. (B) Immunohistochemistry of HAb18G/CD147 and β1,6‐GlcNAc‐branched N‐glycans and PLA assay of CD147‐β1,6‐GlcNAc branching in the same tumor tissues (400×). Scale bar = 20 μm. (C) In situ PLA detecting CD147 with β1,6‐GlcNAc‐branched structures in human HCC tissue stage 0--A and stage C HCC tissue. Scale bar = 50 μm. (D) Quantitation of PLA signals. p = 0.002 (stage C versus 0--A); p = 0.018 (stage C versus B); p = 0.685 (stage B versus 0--A). \*p \< 0.05; \*\*p \< 0.01; one‐way ANOVA.](PATH-245-41-g002){#path5054-fig-0002}

###### 

Correlation between aberrant glycosylation of CD147/basigin mediated by GnT‐V and prognostic variables in 51 HCC patients. Statistical significance of differences between groups was analyzed by the Wilcoxon rank sum test

                       **PLA signal CD147/PHA‐L**  
  ------------------- ---------------------------- -------
  Sex                                               0.375
  Male (*n =* 38)         13.48 (5.41--30.48)      
  Female (*n =* 11)       11.43 (8.07--18.37)      
  Age (years)                                       0.829
  \<50 (*n =* 22)         11.63 (5.41--30.80)      
  50 (*n =* 15)            12.8 (6.04--20.40)      
  Liver cirrhosis                                   0.335
  Yes (*n =* 30)          13.64 (5.41--30.48)      
  No (*n =* 19)           11.43 (7.59--20.40)      
  BCLC stage                                        0.016
  0--A (*n =* 15)         10.05 (5.41--17.65)      
  B--C (*n =* 36)         14.60 (6.04--30.48)      
  PVT                                               0.242
  Yes (*n =* 9)           13.54 (10.42--20.40)     
  No (*n =* 26)           12.00 (6.04--26.54)      
  Number of tumors                                  0.133
  \< 3 (*n =* 44)         12.63 (5.41--30.48)      
  \> 3 (*n =* 5)          15.49 (13.54--18.37)     
  Tumor size (cm)                                   0.080
  ≤ 5 (*n =* 19)          12.46 (5.41--18.45)      
  \> 5 (*n =* 31)         14.28 (6.04--30.48)      
  Serum AFP (μg/l)                                  0.178
  ≤ 25 (*n =* 10)         12.06 (7.59--18.32)      
  \> 25 (*n =* 38)        13.80 (5.41--30.48)      
                                                   

PHA‐L = biotinylated Phaseolus vulgaris leucoagglutinin; PLA = proximity ligation assay.

GnT‐V‐mediated glycosylation promotes CD147/basigin‐mediated invasion in HCC cells {#path5054-sec-0017}
----------------------------------------------------------------------------------

We next assessed the effect of GnT‐V‐mediated glycosylation of CD147/basigin on the invasive properties of HCC cells. Inhibition of β1,6‐branching synthesis using 1 μg/ml swainsonine (supplementary material, Figure [S2](#path5054-supitem-0003){ref-type="supplementary-material"}) or attenuation of *MGAT5* expression with siRNA (si‐*MGAT5*) markedly reduced cell invasion and migration (Figure [3](#path5054-fig-0003){ref-type="fig"}A, B). To determine the effect of β1,6‐branched *N‐*glycosylation, we stimulated Huh‐7 and HepG2 cells with purified wild‐type or with mutant CD147/basigin with defective β1,6‐branched *N‐*glycosylation, and then analyzed MMP expression (Figure [3](#path5054-fig-0003){ref-type="fig"}C, D). Real‐time PCR showed that *MMP‐1*, *MMP‐2*, and *MMP‐9* were reduced in cells treated with mutant CD147/basigin (defective β1,6‐branched *N‐*glycosylation) compared with cells treated with wild‐type, suggesting that GnT‐V‐mediated glycosylation increases CD147/basigin‐mediated HCC cell invasion (Figure [3](#path5054-fig-0003){ref-type="fig"}D).

![β1,6‐GlcNAc‐branched structures on CD147 promote invasion and metastasis in HCC cells. (A, B) Invasive potential of Huh‐7 cells. (A) Representative images. (B) Quantification of +sw (treatment with 1 μg/ml swainsonine for 48 h) and the effect of MGAT5 silencing. (C) Huh‐7 and HepG2 cells treated with 1 μg/ml swainsonine (sw) for 48 h were subjected to CD147/HAb18G immunoprecipitation and western blotting. (D) Actively growing HepG2 and Huh‐7 cells were treated with purified CD147 protein (1 μg/ml) for 24 h. The mRNA levels of MMP‐1, MMP‐2, and MMP‐9 in HepG2 and Huh‐7 cells were quantitated by real‐time PCR. Data are presented as the mean ± SD of three independent experiments. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](PATH-245-41-g003){#path5054-fig-0003}

β1,6‐GlcNAc glycans are required for the interaction between CD147/basigin and integrin β1 {#path5054-sec-0018}
------------------------------------------------------------------------------------------

Integrin β1 is one of the most predominant interacting partners of CD147/basigin [18](#path5054-bib-0018){ref-type="ref"}. To assess the contribution of *N‐*glycosylation to the interaction with integrin β1, we constructed WT‐CD147‐GFP and 3Q‐CD147‐GFP plasmids (Figure [4](#path5054-fig-0004){ref-type="fig"}A). After transfection into HEK293T cells, a strong green fluorescence signal was observed by fluorescence microscopy (supplementary material, Figure [S3](#path5054-supitem-0004){ref-type="supplementary-material"}). When integrin β1 was immunoprecipitated from cell lysates, the precipitated GFP levels were much lower in 3Q‐293 T cells than in WT‐293 T cells (Figure [4](#path5054-fig-0004){ref-type="fig"}B). The reverse was also true, suggesting that 3Q‐CD147 is less efficient at binding integrin β1 than WT‐CD147, and indicating that the binding of CD147/basigin to integrin β1 is affected by *N‐*glycosylation. We next analyzed the interaction of integrin β1 and CD147/basigin by PLA. When β1,6‐GlcNAc glycan synthesis was inhibited for 48 h by swainsonine or si‐*MGAT5* (Figure [4](#path5054-fig-0004){ref-type="fig"}C--F), there was a decrease in the ability of CD147/basigin to bind integrin β1. β1,6‐GlcNAc glycans are the preferred binding partners of galectin‐3, an *N‐*glycan‐binding ligand, in the formation of functional extracellular galectin glycoprotein lattices [34](#path5054-bib-0034){ref-type="ref"}. To further confirm the role of β1,6‐GlcNAc glycans in this interaction, we silenced *LGALS3* gene expression using siRNA. As determined by co‐IP and western blotting, si‐*LGALS3* reduced the interaction between CD147/basigin and integrin β1 compared with control (Figure [4](#path5054-fig-0004){ref-type="fig"}G, H). These findings clearly establish the importance of β1,6‐GlcNAc glycans for the binding of CD147/basigin to integrin β1, consistent with the previous result that CD147/basigin‐β1,6‐branched glycans are associated with metastasis.

![CD147/basigin‐β1,6‐GlcNAc branching is required for the interaction with integrin β1. (A) Schematic diagram of the CD147/basigin protein. Full‐length protein was separated into the extracellular domain (ECD) and the intracellular domain (ICD). SP = signal peptide; TM = transmembrane domain. Three N‐glycosylation sites in the ECD domain are labeled in blue (numbers indicate amino acid position). (B) Co‐IP of HEK293T cells transfected with WT‐CD147‐GFP or 3Q‐CD147‐GFP plasmid. Left: CD147‐GFP was immunoprecipitated with anti‐integrin β1 and detected using anti‐GFP (upper panel); 1/10th of the total cell lysate was analyzed as input protein (lower panel). Right: integrin β1 was immunoprecipitated with GFP and CD147‐GFP was detected using anti‐GFP antibodies (upper panel; red arrow indicates a higher level of heavily glycosylated 3Q‐CD147 than WT‐CD147); 1/10th of the total cell lysate was analyzed as input protein (lower panel). (C, D) Fluorescence signal and in situ PLA analysis of the interaction between CD147 and integrin β1 under the indicated conditions (sw, 1 μg/ml). Scale bar = 50 μm. (E, F) Fluorescence signal and in situ PLA analysis of the interaction between CD147 and integrin β1 after silencing MGAT5. Scale bar = 50 μm. (G, H) Co‐IP of CD147 and integrin β1 in HepG2 and Huh‐7 cells transfected with either siRNAs targeting LGALS3 (Gal‐3) or nonspecific control (NC) siRNA. (G) Immunoprecipitation with HAb18G/CD147 antibodies (upper panel); input proteins were detected (lower panel). (H) Immunoprecipitation with integrin β1 antibodies (upper panel); input proteins were detected (lower panel). In G and H, the input represents 1/10th of the total cell lysate (comprising si‐Gal‐3 and NC samples mixed with IgG). All data are presented as the mean ± SD of three independent experiments. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](PATH-245-41-g004){#path5054-fig-0004}

The PI3K/Akt signaling pathway is involved in the regulation of GnT‐V expression {#path5054-sec-0019}
--------------------------------------------------------------------------------

CD147/basigin interacts with integrin β1 and activates the PI3K/Akt pathway. To investigate whether GnT‐V is linked to the PI3K pathway, we treated HepG2 and Huh‐7 cells with 10 μmol/l LY294002, a PI3K inhibitor [36](#path5054-bib-0036){ref-type="ref"}. Western blotting and qPCR showed that GnT‐V and Gal‐3 were decreased by LY294002 (Figure [5](#path5054-fig-0005){ref-type="fig"}A--C). As shown in Figure [4](#path5054-fig-0004){ref-type="fig"}, β1,6‐GlcNAc glycans regulated the CD147/basigin--integrin β1 interaction. To determine whether they also regulate the downstream PI3K pathway, we analyzed activation of downstream proteins, including FAK, paxillin, and Akt. Depletion of β1,6‐branched *N‐*glycans impaired PI3K pathway activation and the subsequent activation of p‐FAK, p‐paxillin, and p‐Akt (Figure [5](#path5054-fig-0005){ref-type="fig"}D); these results were comparable to those of previous studies [36](#path5054-bib-0036){ref-type="ref"}, [37](#path5054-bib-0037){ref-type="ref"}. Taken together, activation of the PI3K/Akt pathway is involved in the regulation of GnT‐V expression and deletion of GnT‐V‐mediated *N‐*glycosylation impairs the PI3K/Akt pathway.

![The PI3K/Akt signaling pathway is involved in the regulation of GnT‐V expression. (A, B) GnT‐V in cells treated with 10 μmol/l LY294002 for 24 h. (A) Western blotting. (B) Real‐time PCR. (C) Real‐time PCR analysis of LGALS3 (Gal‐3) in cells treated with 10 μmol/l LY294002 for 24 h. (D) Western blotting of PI3K‐dependent signaling under the indicated conditions (sw, 1 μg/ml). All data are presented as the mean ± SD (n = 3). \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.](PATH-245-41-g005){#path5054-fig-0005}

Discussion {#path5054-sec-0020}
==========

In the current study, we determined how β1,6‐branched *N‐*glycans contribute to the biological functions of CD147/basigin in HCC metastasis. EMT is an important process for metastasis [38](#path5054-bib-0038){ref-type="ref"} and emerging evidence suggests a correlation between GnT‐V and EMT. The expression of GnT‐V is elevated during EMT [39](#path5054-bib-0039){ref-type="ref"}, [40](#path5054-bib-0040){ref-type="ref"} and GnT‐V overexpression promotes TGF‐β‐induced EMT and enhances the metastasis of multiple types of carcinoma [41](#path5054-bib-0041){ref-type="ref"}, [42](#path5054-bib-0042){ref-type="ref"}. However, some inconsistent results have also been reported; for example, GnT‐V was reported to suppress EMT in lung cancer cells [43](#path5054-bib-0043){ref-type="ref"}. Our research showed that GnT‐V was upregulated during TGF‐β1‐induced EMT in hepatocytes. In our previous study, we characterized the role of CD147/basigin in promoting EMT in HCC progression at the transcriptional level, and we thus wondered whether GnT‐V‐mediated *N‐*glycosylation of CD147/basigin changes during EMT. Analysis of CD147/basigin‐β1,6‐branching confirmed that modifications were increased, implying that β1,6‐branched glycans are involved in the functions of CD147/basigin in metastasis.

We confirmed this finding in patients with HCC by quantifying the levels of CD147/basigin‐β1,6‐branched glycans in HCC tissues *in situ*. The positive correlation between the level of branched CD147/basigin‐β1,6‐glycans and BCLC stage indicates that CD147/basigin‐β1,6‐branching is correlated with HCC metastasis. As mentioned previously, CD147/basigin was initially identified as an inducer of MMPs (termed EMMPRIN; extracellular matrix metalloproteinase inducer) and MMPs are often increased in cancer in correlation with tumor invasiveness and metastasis. Inhibiting the addition of β1,6‐branched glycans onto CD147/basigin with swainsonine decreased MMP expression in HepG2 and Huh‐7 cells. In contrast, overexpression of GnT‐V increased the level of CD147/basigin‐β1,6‐branching and the induction of MMPs [22](#path5054-bib-0022){ref-type="ref"}. These results suggest that the GnT‐V‐mediated *N‐*glycosylation of CD147/basigin increases its biological activity in metastasis.

*N‐*glycosylation plays a role in protein--protein interactions [44](#path5054-bib-0044){ref-type="ref"}, [45](#path5054-bib-0045){ref-type="ref"}, [46](#path5054-bib-0046){ref-type="ref"}. CD147/basigin interacts with integrin β1 to modulate integrin‐dependent signaling and FAK activation, leading to downstream events such as stimulation of the Rac/Ras/Raf/ERK and PI3K/Akt pathways, and enhancing the invasive and metastatic potential of HCC cells [47](#path5054-bib-0047){ref-type="ref"}. Although the effects of *N‐*glycosylation on integrin β1 binding to other proteins have been partially revealed, the fundamental mechanism by which glycans affect this interaction is not well understood [46](#path5054-bib-0046){ref-type="ref"}, [48](#path5054-bib-0048){ref-type="ref"}. We explored whether β1,6‐branched glycans play a role in the interaction between CD147/basigin and integrin β1. PLA showed that the binding of CD147/basigin to integrin β1 was decreased when β1,6‐branched glycan synthesis was inhibited or when *MGAT5* expression was silenced, and silencing *LGALS3* had a similar effect. These results reveal that β1,6‐branched glycans play a crucial role in the interaction between CD147/basigin and integrin β1. However, inhibiting *N‐*glycosylation of CD147/basigin did not fully abrogate the interaction (Figure [4](#path5054-fig-0004){ref-type="fig"}B), suggesting that other factors are involved, as previously reported [47](#path5054-bib-0047){ref-type="ref"}. In addition, β1,6‐branched glycans might act as co‐receptors to promote the interaction between CD147/basigin and integrin β1. Based on these results, we conclude that β1,6‐glycans modulate CD147/basigin‐mediated functions in metastasis.

Accumulating evidence suggests that activated FAK--paxillin and FAK--PI3K signaling pathways are actively engaged in the migratory process in metastatic cancer cells [49](#path5054-bib-0049){ref-type="ref"}. Our laboratory previously discovered that PI3K signaling enhances the metastatic potential of HCC cells, which is closely correlated with CD147/basigin expression [15](#path5054-bib-0015){ref-type="ref"}, [50](#path5054-bib-0050){ref-type="ref"}. While *MGAT5* expression is reportedly regulated by the RAS--RAF--MAPK signaling pathway [8](#path5054-bib-0008){ref-type="ref"}, the regulatory effect of the PI3K pathway on *MGAT5* has not yet been revealed. The current study showed that the PI3K/Akt pathway regulates GnT‐V expression and the *N‐*glycosylation of CD147/basigin. CD147/basigin interacts with integrin β1 and activates the downstream FAK--PI3K pathway, and inhibition of β1,6‐glycans decreased this interaction. Thus, inhibition of β1,6‐glycans would theoretically attenuate the PI3K pathway, and we verified this phenomenon in Huh‐7 and HepG2 cells. Interruption of β1,6‐branched glycans by swainsonine suppressed the PI3K/Akt pathway, and these results were comparable to those reported by Guo *et al* [37](#path5054-bib-0037){ref-type="ref"}. Moreover, the PI3K pathway regulates EMT [51](#path5054-bib-0051){ref-type="ref"}. The levels of GnT‐V and CD147/basigin‐β1,6‐branched glycans were upregulated during EMT, which enhanced the interaction with integrin β1 (Figure [4](#path5054-fig-0004){ref-type="fig"}), further promoting PI3K/Akt pathway activation [15](#path5054-bib-0015){ref-type="ref"} and enhancing the invasive and metastatic potential of HCC cells. However, it should be noted that GnT‐V mediates the glycosylation of not only CD147/basigin but also all proteins that contain β1,6‐branching. Using CD147/basigin as a model, our data suggest that β1,6‐branching affects the affinity and biological functions of many other glycoproteins.

Based on the findings of this study, we propose a model to explain the molecular mechanism of GnT‐V in HCC progression (Figure [6](#path5054-fig-0006){ref-type="fig"}). During EMT, transcription factors accumulate in the nuclei of cancer cells to activate GnT‐V expression. The modification of surface molecules such as CD147/basigin with β1,6‐branched glycans is increased, which alters the response of cancer cells to their microenvironment. These alterations lead to changes in cell behavior, facilitating metastasis. In addition, β1,6‐GlcNAc‐branched *N‐*glycans regulate the interaction of CD147/basigin with integrin β1 and the associated downstream signaling events. Moreover, the PI3K/Akt signaling pathway regulates GnT‐V expression, and the products of this enzyme affect PI3K/Akt signaling.

![Proposed positive feedback loop for the regulation of PI3K/Akt and GnT‐V to promote HCC metastasis. During EMT, transcription factors (TFs) accumulate in the nuclei of cancer cells to activate GnT‐V expression. GnT‐V then leads to global alteration of β1,6‐branched glycans on cell surface molecules, including CD147/basigin, altering the response of cancer cells to their microenvironment, which consequently promotes metastasis. When the PI3K/Akt pathway is inhibited, GnT‐V expression decreases; furthermore, PI3K signaling is suppressed when the synthesis of β1,6‐GlcNAc‐branched N‐glycans catalyzed by GnT‐V is interrupted.](PATH-245-41-g006){#path5054-fig-0006}

In conclusion, we have demonstrated a novel mechanism by which β1,6‐branched *N‐*glycans regulate the activity of CD147/basigin in the metastasis of HCC cells, and these modifications are critical for EMT and the interaction with integrin β1. In addition, we propose a feedback model in which the PI3K/Akt pathway regulates GnT‐V expression, and this enzyme then enhances the PI3K signal. Our study not only reveals the pathological role and regulatory mechanism of GnT‐V‐mediated modification of CD147/basigin during HCC progression but also sheds light on promising prognostic factors and personalized therapeutic leads to target HCC and possibly other cancers.
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**Figure S1.** Confocal microscopy images of CD147 (green) and β1,6‐GlcNAc‐branched N‐glycans (red) showing subcellular localization and nuclear DAPI staining in HepG2 and Huh‐7 cells. Scale bars = 10 and 20 μm.
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**Figure S2.** Western blotting analysis of HAb18G/CD147 expression in HepG2 and Huh‐7 cells treated with various concentrations of swainsonine for 48 h.
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**Figure S3.** Immunofluorescence of HEK293T cells transfected with WT‐CD147‐GFP and 3Q‐CD147‐GFP plasmids.
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**Table S1.** Antibody details

**Table S2.** shRNA and quantitative real‐time PCR primer sequences
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